Cardiol Rev 2021 Mar 19. Epub 2021 Mar 19.
Mayo Clinic, Rochester, MN Division of Cardiology, University of Pittsburgh Medical Centre Heart and Vascular Institute, Pittsburgh, PA Garden City Hospital, Garden City, MI Sinai Hospital of Baltimore, Baltimore, MD Johns Hopkins University School of Medicine, Baltimore, MD.
Antiplatelet agents are the standard of practice in the management of atherosclerosis and acute coronary syndrome (ACS). In contrast to the available antiplatelet agents, vorapaxar represents a novel mechanism of action. It is an antagonist of the platelet protease-activated receptor-1 (PAR-1) and inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)- induced platelet aggregation. Read More